Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, novembre 20
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
AEON Biopharma Inc
AEON
AMEX
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.1230
-0.0101
-7.59%
À la clôture: Nov 20, 4:00 PM EST
$0.1280
0.005
4.07%
Après les heures: 5:09 PM EST
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Données financières
Sentiment
Actionnariat
Comparer
Rapport sur les stocks
Résultats:
Les résultats Q3 2026 ont été publiés le lun. nov. 16th, après la fermeture du marché
AEON Biopharma Financials
AEON Biopharma (AEON) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
AEON Biopharma Q3 EPS $0.01 Beats $(0.08) Estimate
AEON Biopharma (AMEX:AEON) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.08) by 112.5 percent. This is a 102.56 percent increase over losses of $(0.39) per share from
Benzinga Newsdesk
PRO
AEON Biopharma Q2 EPS $(0.02) Beats $(0.12) Estimate
AEON Biopharma (AMEX:AEON) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.12) by 83.33 percent. This is a 96.67 percent increase over losses of $(0.60) per share from the
Benzinga Newsdesk
PRO
AEON Biopharma Q1 EPS $(0.29) Misses $(0.13) Estimate
AEON Biopharma (AMEX:AEON) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.13) by 141.67 percent. This is a 112.72 percent decrease over earnings of $2.28 per share from
Benzinga Newsdesk
PRO
AEON Biopharma Q4 EPS $(3.72)
AEON Biopharma (AMEX:AEON) reported quarterly losses of $(3.72) per share. This is a 199.2 percent decrease over earnings of $3.75 per share from the same period last year.
Benzinga Newsdesk
PRO
AEON Biopharma Q3 EPS $(0.39) Beats $(0.43) Estimate
AEON Biopharma (AMEX:AEON) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 96.61 percent increase over losses of $(11.52) per share from the
Benzinga Newsdesk
PRO
AEON Biopharma Q2 EPS $(0.60) Beats $(11.52) Estimate
AEON Biopharma (AMEX:AEON) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(11.52) by 94.79 percent. This is a 100.2 percent decrease over earnings of $304.00 per share from
Benzinga Newsdesk